HRAS and salivary gland carcinoma: The farnesyltransferase inhibitor trials were initiated based, in part, on HRAS-mutant mammary and salivary carcinoma mouse models (60), where it was determined that if HRAS is not farnesylated, it cannot be properly localized to the plasma membrane and therefore cannot signal.